IQM Quantum Computers Unveils Development Roadmap Focused on Fault-tolerant Quantum Computing by 2030
IQM Quantum Computers (IQM), a global leader in superconducting quantum computing, today announced its development roadmap with technical milestones targeting fault tolerant quantum computing by 2030, while enabling a dedicated Noisy Intermediate-Scale Quantum (NISQ) approach for near-term usage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113963297/en/
IQM Quantum Computers Development Roadmap (Graphic: Business Wire)
Since its start, IQM has successfully delivered full-stack quantum computers based on its first three processor generations. IQM's 12-year roadmap reflects its vision for pioneering quantum solutions through novel algorithmic approaches, modular software integration, and scalable hardware advancements. It leverages the company's ability to design and fabricate next-generation quantum processors with seamless integration into full-stack systems controlled by an open software stack.
IQM's unique co-design capabilities steer the roadmap towards efficient error-correction implementations with high system performance by merging IQM's two processor topologies IQM Star and IQM Crystal. To enable the roadmap, IQM systematically invests in its R&D, testing and fabrication facilities to boost technology scaling up to 1 million qubits while maintaining high qubit quality and gate fidelity.
To support the developer community and to ease the usage of quantum computing, IQM will also enable tight high-performance computing (HPC) integration and create a special software development kit (SDK). Open interfaces will empower the ecosystem, including quantum error mitigation, co-develop libraries and use-cases on IQM’s quantum computers.
The company aims to achieve quantum advantage across multiple industry domains, focusing on quantum simulations, optimization, and quantum machine learning. According to a McKinsey report, these selected use-cases will unlock a value potential of more than US$28 billion by 2035.
Quantum advantage will be provided by fully error-corrected systems with hundreds to thousands of high-precision logical qubits, for which error correction will be enabled by efficiently implementing novel quantum low-density parity-check (QLDPC) codes. This approach reduces the hardware overhead by a factor of up to 10 compared to surface code implementation.
Furthermore, IQM is targeting high-precision logical qubits with error rates below 10^-7, enabling quantum advantage for applications demanding exceptional accuracy, such as in chemistry and materials science.
“We are implementing Quantum low-density parity-check (QLDPC) codes through a novel chip topology, enabled by our uniquely connected Star topology, long-distance couplers and a very compact approach for advanced packaging and signal routing,” said Dr. Jan Goetz, Co-Founder and Co-CEO of IQM Quantum Computers. “This underlines our commitment to hardware efficiency, enabling a feasible and scalable pathway to fault tolerance combined with an open and modular software architecture.”
Goetz emphasizes that the company’s proprietary cleanroom facilities will support the fabrication of complex processors with unique long-range connections, facilitating high-performance quantum processors.
To this end, IQM will implement novel solutions for advanced packaging and 3D integration to ensure scalability while maintaining its ambitious goals to reduce error rates, while its large-scale processors will be built up in a modular way and powered by cryogenic electronics. The results are reduced heat load, strongly miniaturized packaging solutions, and reduced cost per qubit. These features will result in more performant and affordable products for IQM's customers in the HPC and enterprise market.
Offering on-premises and cloud access, IQM has been specializing in integrating quantum systems into HPC centers since 2020. The latest is Germany’s first hybrid quantum computer at the Leibniz Supercomputing Centre.
IQM aims to explain further details of the roadmap in future publications, blog posts, and at industry and academic events.
About IQM Quantum Computers:
IQM is a global leader in designing, building, and selling superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers anywhere in the world. IQM customers include the leading high-performance computing centres, research labs, universities and enterprises which have full access to IQM's software and hardware. IQM has over 280 employees with offices in Espoo, Madrid, Munich, Paris, Palo Alto, Singapore and Warsaw.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113963297/en/
Contacts
Email: press@meetiqm.com
Mobile: +358504790845
www.meetiqm.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.meetiqm.co
m%2F&esheet=54152085&newsitemid=20241113963297&lan=en-US&anchor=www.meetiqm.com&
index=2&md5=0e164a7e428807f4e256044fee302953
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom